REG - Centrica PLC - Completion of investment in Sizewell C

CentricaAnnouncement

Today 12:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251104:nRSD1406Ga&default-theme=true

RNS Number : 1406G  Centrica PLC  04 November 2025

 

Centrica plc

4(th) November 2025

 

Completion of investment in Sizewell C

Centrica plc (the "Company") is pleased to announce the completion of its
acquisition of a 15% equity stake in Sizewell C(1) following financial close
and revenue commencement which occurred earlier today. As part of completion,
Centrica plc has made an initial investment of £376 million into Sizewell C,
which includes funding of the regulated asset base value built up prior to
financial close and pre-funding a portion of 2026 construction costs. We now
expect to make a cumulative investment of £500 - 600 million into Sizewell C
through to the end of 2028 as part of our capped £1.3 billion investment.

 

Chris O'Shea, Group Chief Executive, Centrica plc, said:

"Today is a significant milestone for the UK, and I'm thrilled that Centrica
is joining forces with exceptional partners to drive this critical project
forward. Sizewell C will be at the heart of Britain's energy future -
delivering reliable, affordable, zero-carbon power that fuels economic growth
for decades to come. This investment goes far beyond building a new power
station; it's a huge commitment to Britain's energy security, our journey to
net zero, and the creation of thousands of high-quality jobs nationwide.

"Centrica's investment in the backbone of the UK's energy system, from
Sizewell C, to Grain LNG, to our partnership with X-energy, is securing the
energy Britain needs today and powering the ambitions of tomorrow. We stand
ready to continue to invest if we see a supportive regulatory framework."

 

Enquiries:

 Centrica
 Investors and Analysts:                              email: ir@centrica.com (mailto:ir@centrica.com)
 Media:                                               email: media@centrica.com (mailto:media@centrica.com)

                                                      tel: +44 (0) 1784 843000

 UBS AG London Branch (Financial Adviser and Broker)  tel: +44 (0) 20 7567 8000

 Jonathan Grundy

 David James

 James Donovan

 George Vowden

 Christopher Binks

 

Slaughter and May is acting as legal adviser to Centrica.

 

Notes:

1.   Further details can be found at www.centrica.com/sizewellc
(http://www.centrica.com/sizewellc)

 

Disclaimer

UBS AG London Branch ("UBS") is authorised and regulated by the Financial
Market Supervisory Authority in Switzerland. It is authorised by the
Prudential Regulation Authority and subject to regulation by the Financial
Conduct Authority and limited regulation by the Prudential Regulation
Authority in the United Kingdom. UBS are acting as financial adviser
exclusively for Centrica and no one else in connection with the matters set
out in this announcement. In connection with such matters, UBS, its
affiliates, and it's or their respective directors, officers, employees and
agents will not regard any other person as its client, nor will it be
responsible to any other person for providing the protections afforded to its
clients or for providing advice in relation to the contents of this
announcement or any other matter referred to herein.

 

END

 

Centrica plc is listed on the London Stock Exchange (CNA)

Registered Office: Millstream, Maidenhead Road, Windsor, Berkshire SL4 5GD

Registered in England & Wales number: 3033654

Legal Entity Identifier number: E26EDV109X6EEPBKVH76

ISIN number: GB00B033F229

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBIBTTMTTMBAA



            Copyright 2019 Regulatory News Service, all rights reserved